CD8A and neoplasm: ICB therapy may be particularly effective when rewiring the metabolic phenotype of effector T cells or targeting cancer metabolism to render tumor cells low-glycolytic activity or low LDHA-expression, thus enabling activated CD8+ T cells to manifest within the tumor microenvironment (Patsoukis et al, 2015).